

- **Name:** Kyung Hwan Kim
  - **Current Position & Affiliation:** Assistant Professor, Department of Radiation Oncology, Yonsei University College of Medicine
  - **Country:** Korea
- 

**• Educational Background:**

- 2016-2020 Ph.D., Immunology  
Graduate School of Medical Science and Engineering (GSMSE), Korea  
Advanced Institute of Science and Technology (KAIST)
- 2013-2015 M.S., Radiation Oncology  
Department of Radiation oncology,  
Yonsei University College of Medicine, Seoul, Korea
- 2005-2011 M.D.  
Yonsei University College of Medicine, Seoul, Korea

**• Professional Experience:**

- 2022- Assistant Professor, Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea
- 2021-2022 Clinical Assistant Professor, Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea
- 2020-2021 Clinical professor, Department of Radiation Oncology, Yonsei Cancer Center, Seoul, Korea
- 2012-2016 Residency, Department of Radiation Oncology  
Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea

**• Professional Organizations:**

Korean Society for Radiation Oncology  
Korean Cancer Association  
Korean Association for Lung Cancer  
Korean Society for Head & Neck Oncology  
Korean Society of Medical Oncology

**• Main Scientific Publications:**

1. Yang G, Yoon HI, Lee J, Kim J, Kim H, Cho J, Lee CG, Chang JS, Cho Y, Kim JS, **Kim KH**. Risk of on-treatment lymphopenia is associated with treatment outcome and efficacy of consolidation immunotherapy in patients with non-small cell lung cancer treated with concurrent chemoradiotherapy. *Radiother Oncol*. 2023 Sep 30;189:109934. doi: 10.1016/j.radonc.2023.109934. Online ahead of print.

2. **Kim KH**, Pyo H, Lee H, Oh D, Noh JM, Ahn YC, Yoon HI, Moon H, Lee J, Park S, Jung HA, Sun JM, Lee SH, Ahn JS, Park K, Ku BM, Ahn MJ, Shin EC. Dynamics of Circulating Immune Cells During Chemoradiotherapy in Patients with Non-Small Cell Lung Cancer Support Earlier Administration of Anti-PD-1/PD-L1 Therapy. *Int J Radiat Oncol Biol Phys*. 2022 Jun 1;113(2):415-425.
3. **Kim KH**, Pyo H, Lee H, Oh D, Noh JM, Ahn YC, Kim CG, Yoon HI, Lee J, Park S, Jung HA, Sun JM, Lee SH, Ahn JS, Park K, Ku BM, Shin EC, Ahn MJ. Association of T cell senescence with radiation pneumonitis in patients with non-small cell lung cancer. *Int J Radiat Oncol Biol Phys*. 2023 Feb 1;115(2):464-475.
4. **Kim KH\***, Kim HK\*, Kim HD, Kim CG, Lee H, Han JW, Choi SJ, Jeong S, Jeon M, Kim H, Koh J, Ku BM, Park SH, Ahn MJ, Shin EC. PD-1 blockade-unresponsive human tumor-infiltrating CD8<sup>+</sup> T cells are marked by loss of CD28 expression and rescued by IL-15. *Cell Mol Immunol*. 2021 Feb;18(2):385-397. doi: 10.1038/s41423-020-0427-6.
5. **Kim KH\***, Hur JY\*, Cho J, Ku BM, Koh J, Koh JY, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ, Shin EC. Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatment. *Oncoimmunology*. 2020 Feb 2;9(1):1722023.
6. **Kim KH**, Cho J, Ku BM, Koh J, Sun JM, Lee SH, Ahn JS, Cheon J, Min YJ, Park SH, Park K, Ahn MJ, Shin EC. The First-week Proliferative Response of Peripheral Blood PD-1+CD8<sup>+</sup> T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors. *Clin Cancer Res*. 2019 Apr 1;25(7):2144-2154.